- Home
- USPH vs CVAC Comparison
USPH vs CVAC Comparison
Compare USPH & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USPH
- CVAC
- Stock Information
- Founded
- USPH 1990
- CVAC 2000
- Country
- USPH United States
- CVAC Germany
- Employees
- USPH N/A
- CVAC N/A
- Industry
- USPH Medical/Nursing Services
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- USPH Health Care
- CVAC Health Care
- Exchange
- USPH Nasdaq
- CVAC Nasdaq
- Market Cap
- USPH 1.4B
- CVAC 1.2B
- IPO Year
- USPH 1992
- CVAC 2020
- Fundamental
- Price
- USPH $78.20
- CVAC $5.25
- Analyst Decision
- USPH Strong Buy
- CVAC Hold
- Analyst Count
- USPH 5
- CVAC 3
- Target Price
- USPH $110.20
- CVAC $6.83
- AVG Volume (30 Days)
- USPH 139.5K
- CVAC 509.6K
- Earning Date
- USPH 11-05-2025
- CVAC 11-12-2025
- Dividend Yield
- USPH 2.04%
- CVAC N/A
- EPS Growth
- USPH 152.91
- CVAC N/A
- EPS
- USPH 2.37
- CVAC 1.01
- Revenue
- USPH $750,948,000.00
- CVAC $599,540,810.00
- Revenue This Year
- USPH $18.73
- CVAC N/A
- Revenue Next Year
- USPH $6.13
- CVAC $23.40
- P/E Ratio
- USPH $37.14
- CVAC $5.21
- Revenue Growth
- USPH 17.51
- CVAC 675.15
- 52 Week Low
- USPH $62.77
- CVAC $2.37
- 52 Week High
- USPH $101.20
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- USPH 30.19
- CVAC 28.08
- Support Level
- USPH $81.32
- CVAC $5.33
- Resistance Level
- USPH $89.57
- CVAC $5.41
- Average True Range (ATR)
- USPH 3.90
- CVAC 0.04
- MACD
- USPH -1.16
- CVAC -0.01
- Stochastic Oscillator
- USPH 20.68
- CVAC 31.22
About USPH U.S. Physical Therapy Inc.
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.